Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 16/20 | 0.62 |
| ▸ | F2 | P00734 | 4/20 | 0.62 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.58 |
| ▸ | PDE4A | P27815 | 3/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.57 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.56 |
| ▸ | CDK2 | P24941 | 1/20 | 0.56 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16948138 | 0.92 | F10 (0.64) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL2000886 | 0.91 | F10 (0.63) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL15731769 | 0.91 | F10 (0.67) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL5307046 | 0.91 | F10 (0.67) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL18660272 | 0.90 | F10 (0.62) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL5453891 | 0.90 | F10 (0.55) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL18040316 | 0.90 | F10 (0.61) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL18040318 | 0.90 | F10 (0.61) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL17572367 | 0.90 | F10 (0.61) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL18058755 | 0.90 | F10 (0.61) | F10F2SLC29A1PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015177801-A1 | NOVEL PROCESS FOR THE PREPARATION OF A LACTAM-CONTAINING COMPOUND | SYMED LABS LIMITED (IN) | 2015-11-26 | — | — | WO | claimed |
| WO-2014108919-A2 | NOVEL INTERMEDIATE AND POLYMORPHS OF 1-(4-METHOXYPHENYL)-7-OXO-6-[4-(2-OXOPIPERIDIN-1-YL)PHENYL]-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3,4-c] PYRIDINE-3-CARBOXAMIDE AND PROCESS THEREOF | MSN LABORATORIES LIMITED (IN) | 2014-07-17 | — | — | WO | claimed |
| WO-2014075648-A1 | A METHOD OF PREPARING APIXABAN | ZENTIVA, K.S. (CZ) | 2014-05-22 | — | — | WO | claimed |
| WO-2021147302-A1 | INTERMEDIATE OF APIXABAN AND PREPARATION METHOD THEREFOR | 浙江九洲药业股份有限公司 | 2021-07-29 | — | — | WO | disclosed |
| EP-3212620-B1 | PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | JUBILANT GENERICS LTD FORMERLY JUBILANT LIFE SCIENCES DIVISION (IN) | 2020-11-25 | — | — | EP | disclosed |
| EP-3212620-B1 | PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | JUBILANT GENERICS LTD FORMERLY JUBILANT LIFE SCIENCES DIVISION (IN) | 2020-11-25 | — | — | EP | disclosed |
| EP-3228619-B1 | PROCESS FOR THE PREPARATION OF APIXABAN | ZAKL FARMACEUTYCZNE POLPHARMA SA (PL) | 2020-07-29 | — | — | EP | disclosed |
| US-20200140436-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-07 | — | — | US | disclosed |
| EP-3190111-B1 | PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES | CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) | 2020-05-06 | — | — | EP | disclosed |
| EP-3190111-B1 | PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES | CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) | 2020-05-06 | — | — | EP | disclosed |
| CN-110894196-A | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | 百时美-施贵宝控股爱尔兰无限公司 | 2020-03-20 | — | — | CN | disclosed |
| US-20050124602-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-09 | — | — | US | disclosed |
| US-20040220174-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-04 | — | — | US | disclosed |
| EP-1467984-A2 | SYNTHESIS OF 4,5-DIHYDRO-PYRAZOLO (3,4-C) PYRID-2-ONES | Bristol-Myers Squibb Company (US) | 2004-10-20 | — | — | EP | disclosed |
| US-6750225-B2 | ANTICOAGULANTS | BRISTOL-MYERS SQUIBB PHARMS COMPANY | 2004-06-15 | — | — | US | disclosed |
| US-20030212054-A1 | Substituted amino methyl factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-13 | — | — | US | disclosed |
| US-20030191115-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-09 | — | — | US | disclosed |
| US-20030181466-A1 | Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-25 | — | — | US | disclosed |
| WO-2003049681-A2 | SYNTHESIS OF 4,5-DIHYDRO-PYRAZOLO [3,4-C] PYRID-2-ONES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| US-20020177713-A1 | 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones useful as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212054-A1 | Substituted amino methyl factor Xa inhibitors | F11, F10, F9 | F10 2/4885F2 12/4885SLC29A1 841/4885 |
| US-20020177713-A1 | 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones useful as factor Xa inhibitors | SERPINC1, SERPINE1, F11 | F10 31/4885F2 8/4885SLC29A1 3538/4885 |
| US-20040220174-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | PEPD, PRSS1, CPB1 | F10 43/4885F2 4/4885SLC29A1 3160/4885 |
| US-20030181466-A1 | Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones | TFPI, TFPI2, F2 | F10 19/4885F2 3/4885SLC29A1 4423/4885 |
| US-20050124602-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | F12, F2, CPB1 | F10 43/4885F2 2/4885SLC29A1 3302/4885 |
| US-20200140436-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | F10 43/4885F2 2/4885SLC29A1 3302/4885 |
| US-20030191115-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | PEPD, HABP2, CPB1 | F10 33/4885F2 13/4885SLC29A1 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.